









市場行情
/
股票
/
nasdaq-tvgn
/

Tevogen Bio Holdings Inc

TVGN

0.380USD

-0.001-0.26%

收盤 12/19, 16:00（美東）報價延遲15分鐘

74.95M總市值

虧損本益比TTM



Tevogen Bio Holdings Inc

0.380

-0.001-0.26%

概覽公司財務分析

概覽

公司

財務

分析

關於 Tevogen Bio Holdings Inc 公司

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

Tevogen Bio Holdings Inc簡介



公司代碼TVGN

公司名稱Tevogen Bio Holdings Inc

上市日期Nov 04, 2021

CEOSaadi (Ryan)

員工數量18

證券類型Ordinary Share

年結日Nov 04

公司地址15 Independence Boulevard, Suite #210

城市WARREN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編07059

電話16468078832

網址https://tevogen.com/

公司代碼TVGN

上市日期Nov 04, 2021

CEOSaadi (Ryan)

Tevogen Bio Holdings Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Kirti Desai

Chief Financial Officer

10.45M

+7.73%

Dr. Neal Flomenberg, M.D.

Chief Scientific Officer and Global R&D Lead

3.53M

+9.28%

Mr. Sadiq Khan

Chief Commercial Officer

1.17M

+20.63%

Mr. Jeffrey Feike

Independent Director

641.77K

-21.90%

Dr. Keow Lin (Lindee) Goh

Independent Director

313.92K

-27.65%

Ms. Susan M. Podlogar

Independent Director

253.92K

-41.48%

Dr. Ryan Saadi, M.D.

Chairman of the Board, Chief Executive Officer

Mr. Victor Sordillo

Independent Director

Dr. Curtis Patton

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Kirti Desai

Chief Financial Officer

10.45M

+7.73%

Dr. Neal Flomenberg, M.D.

Chief Scientific Officer and Global R&D Lead

3.53M

+9.28%

Mr. Sadiq Khan

Chief Commercial Officer

1.17M

+20.63%

Mr. Jeffrey Feike

Independent Director

641.77K

-21.90%

Dr. Keow Lin (Lindee) Goh

Independent Director

313.92K

-27.65%

Ms. Susan M. Podlogar

Independent Director

253.92K

-41.48%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Saadi (Ryan H)

62.67%

Patel (Manmohan)

6.72%

Desai (Kirti)

5.11%

Flomenberg (Neal)

1.78%

BlackRock Institutional Trust Company, N.A.

0.65%

其他

23.07%

持股股東

佔比

Saadi (Ryan H)

62.67%

Patel (Manmohan)

6.72%

Desai (Kirti)

5.11%

Flomenberg (Neal)

1.78%

BlackRock Institutional Trust Company, N.A.

0.65%

其他

23.07%

股東類型

持股股東

佔比

Individual Investor

78.18%

Investment Advisor

1.68%

Investment Advisor/Hedge Fund

0.74%

Research Firm

0.09%

Bank and Trust

0.02%

其他

19.27%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

115

5.02M

2.55%

-6.01M

2025Q2

119

160.27M

86.89%

+1.70M

2025Q1

118

155.00M

115.37%

-16.72M

2024Q4

153

163.30M

93.29%

-39.38M

2024Q3

144

166.12M

95.10%

-39.63M

2024Q2

138

166.33M

103.53%

-38.91M

2024Q1

118

165.09M

105.20%

-36.99M

2023Q4

105

14.20M

68.79%

-44.82M

2023Q3

104

15.77M

75.02%

-42.16M

2023Q2

101

9.09M

32.79%

-42.84M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Saadi (Ryan H)

124.99M

63.54%

-20.00K

-0.02%

Aug 15, 2025

Patel (Manmohan)

13.35M

6.79%

+2.43M

+22.26%

Apr 30, 2025

Desai (Kirti)

10.45M

5.31%

+750.00K

+7.73%

Jun 27, 2025

Flomenberg (Neal)

3.53M

1.8%

+300.00K

+9.28%

Jun 27, 2025

BlackRock Institutional Trust Company, N.A.

1.22M

0.62%

+573.09K

+88.87%

Jun 30, 2025

Khan (Sadiq)

1.17M

0.59%

+200.00K

+20.63%

Jun 27, 2025

The Vanguard Group, Inc.

1.09M

0.55%

+50.31K

+4.83%

Jun 30, 2025

Patton (Curtis L)

1.03M

0.52%

-180.00K

-14.88%

Apr 30, 2025

Feike (Jeffrey L)

641.77K

0.33%

-180.00K

-21.90%

Apr 30, 2025

Geode Capital Management, L.L.C.

542.02K

0.28%

+55.63K

+11.44%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

ProShares Ultra Nasdaq Biotechnology

0.01%

Invesco Nasdaq Biotechnology ETF

0.01%

iShares Micro-Cap ETF

Proshares Ultra Russell 2000

iShares Biotechnology ETF

ProShares Hedge Replication ETF

iShares Russell 2000 Growth ETF

iShares Russell 2000 Value ETF

ProShares UltraPro Russell2000

Global X Russell 2000 ETF

ProShares Ultra Nasdaq Biotechnology

佔比0.01%

Invesco Nasdaq Biotechnology ETF

佔比0.01%

iShares Micro-Cap ETF

佔比0%

Proshares Ultra Russell 2000

佔比0%

iShares Biotechnology ETF

佔比0%

ProShares Hedge Replication ETF

佔比0%

iShares Russell 2000 Growth ETF

佔比0%

iShares Russell 2000 Value ETF

佔比0%

ProShares UltraPro Russell2000

佔比0%

Global X Russell 2000 ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Tevogen Bio Holdings Inc的前五大股東是誰？



Tevogen Bio Holdings Inc的前五大股東如下：
Saadi (Ryan H)
持有股份：124.99M
佔總股份比例：63.54%。
Patel (Manmohan)
持有股份：13.35M
佔總股份比例：6.79%。
Desai (Kirti)
持有股份：10.45M
佔總股份比例：5.31%。
Flomenberg (Neal)
持有股份：3.53M
佔總股份比例：1.80%。
BlackRock Institutional Trust Company, N.A.
持有股份：1.22M
佔總股份比例：0.62%。